search
Back to results

Flaxseed Lignan Supplementation in Elderly Participants With Stage I Hypertension

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 2
Locations
Canada
Study Type
Interventional
Intervention
BeneFlax®
Walking training
Flexibility training
Placebo (Whey Protein)
Dash Eating Plan
Sponsored by
University of Saskatchewan
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring High normal blood pressure, Stage I

Eligibility Criteria

60 Years - 90 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • High normal blood pressure (130/85 - 139/89) or stage I hypertension (140/90 - 150/90)
  • Ability to follow simple instructions

Exclusion Criteria:

  • Age below 60 years.
  • Individuals living in long term care homes.
  • Individuals unable to walk for 30 minutes.
  • Unstable diabetes, or diabetics taking insulin (note: eligible diabetic participants will undergo additional testing during the study ).
  • Current cancer or diagnosed with cancer in the past 2 years.
  • Significant liver or other gastrointestinal disorder including inflammatory bowel disease. (While constipation is the most common gastrointestinal problem in the elderly, it would not be a contraindication)
  • Significant kidney disorder.
  • Have taken oral antibiotics in the past three months
  • Unstable or severe cardiac disease, recent myocardial infarction, or stroke (either in past 6 months or significantly affecting physical mobility).
  • Unstable other medical disease including, but not limited to, pulmonary disorder, epilepsy and genitourinary disorder.
  • Migraine with aura within the last year (as this is a risk factor for stroke).
  • Current diagnosis of a bleeding condition, or at risk of bleeding.
  • Significant immune-compromise.
  • Current use of hormone replacement therapy (except thyroid).
  • Current use of blood pressure medications and/or diuretics
  • Current use of flax seed supplement
  • Participation in any other clinical trial with an investigational agent within one month prior to randomization.

Sites / Locations

  • College of Pharmacy, University of Saskatchewan

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Placebo Comparator

Experimental

Sham Comparator

Arm Label

BeneFlax® + walking training (Dash)

Placebo + walking training (Dash)

BeneFlax® + flexibility training (Dash)

Placebo + flexibility training (Dash)

Arm Description

BeneFlax (0.8 g, twice a day) with exercise training (30-60 minutes walking training, 5 times a week) for 8 weeks; all participants encouraged to follow Dash Eating Plan.

Placebo (whey powder isocaloric to BeneFlax) with exercise training (30-60 minutes walking training, 5 times a week) for 8 weeks; all participants encouraged to follow Dash Eating Plan.

BeneFlax (0.8 g, twice a day) with placebo exercise training (flexibility training, 5 times a week) for 8 weeks; all participants encouraged to follow Dash Eating Plan.

Placebo (whey powder isocaloric to BeneFlax) with placebo exercise training (flexibility training, 5 times a week) for 8 weeks; all participants encouraged to follow Dash Eating Plan.

Outcomes

Primary Outcome Measures

Change in 24 h ambulatory systolic blood pressure
Reduction in 24 h ambulatory systolic blood pressure at midpoint (week 4) and end (week 8) of the intervention relative to baseline value is the primary outcome of the intervention.

Secondary Outcome Measures

Change in body weight
Change in body weight at midpoint (week 4) and end (week 8) of the intervention relative to baseline value.
Heart rate
Glucometer fasting blood glucose
Diabetes only; Blood glucose monitored to ensure intervention does not result in hypoglycemia.
Change in blood markers of safety and cardiovascular disease risk factors (clinical biochemical panel including fasting glucose, lipids, cholesterol, electrolytes, C-reactive protein)
These parameters will be measured individual but reviewed as a composite to confirm safety and any change in cardiovascular disease risk.
Blood levels of the flax lignan, secoisolariciresinol diglucoside (SDG), and its metabolites
Physical activity assessment tool (PASE)
Block Food Frequency Questionnaire
Change in Body composition by DXA (Dual-energy X-ray absorptiometry)
Change in body composition at midpoint (week 4) and end (week 8) of the intervention relative to baseline value.
Heart Rate
Heart Rate
Change in lying and standing blood pressure
Change in lying and standing blood pressure at midpoint (week 4) and end (week 8) of the intervention relative to baseline value.
Respiratory rate
Respiratory rate
Respiratory rate
Block Food Frequency Questionnaire
Blood levels of the flax lignan, secoisolariciresinol diglucoside (SDG), and its metabolites
Glucometer fasting blood glucose
Diabetes only; Blood glucose monitored to ensure intervention does not result in hypoglycemia.
Glucometer fasting blood glucose
Diabetes only; Blood glucose monitored to ensure intervention does not result in hypoglycemia.

Full Information

First Posted
February 28, 2015
Last Updated
January 8, 2018
Sponsor
University of Saskatchewan
search

1. Study Identification

Unique Protocol Identification Number
NCT02391779
Brief Title
Flaxseed Lignan Supplementation in Elderly Participants With Stage I Hypertension
Official Title
Flaxseed Lignan Enriched Complex for Blood Pressure Reduction in Elderly Participants With High Normal Blood Pressure or Stage I Hypertension
Study Type
Interventional

2. Study Status

Record Verification Date
January 2018
Overall Recruitment Status
Completed
Study Start Date
May 2015 (undefined)
Primary Completion Date
July 2017 (Actual)
Study Completion Date
July 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Saskatchewan

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Current recommendations today suggest that use of therapeutic lifestyle changes, such as supplementation with specific dietary components and moderate exercise, are appropriate interventions for individuals with borderline high blood pressure. Dietary intervention with natural products, such as flaxseed, is associated with decreased prevalence of cardiovascular disease (Adolphe 2010). Lignans are the active compounds in flaxseed believed to mediate the cardiovascular health benefits following flaxseed consumption (Peterson 2010). Clinical trials indicate benefit of Flax Lignan Enriched Complex (FLC) (BeneFlax® from Archer Daniels Midland, a natural product derived from flaxseed composed of 34-38% lignan) for reducing blood cholesterol and glucose (Pan 2007; Zhang 2008) and blood pressure (Cornish 2009). Furthermore, a recent study in atherosclerosis patients showed significant clinical benefit of flaxseed meal for reducing blood pressure (Rodriguez-Leyva 2013). As a therapeutic lifestyle change that could prevent a need to introduce drug therapy in elderly patients, the effectiveness of FLC supplementation alone or in combination with moderate exercise merits investigation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
High normal blood pressure, Stage I

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Factorial Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
BeneFlax® + walking training (Dash)
Arm Type
Experimental
Arm Description
BeneFlax (0.8 g, twice a day) with exercise training (30-60 minutes walking training, 5 times a week) for 8 weeks; all participants encouraged to follow Dash Eating Plan.
Arm Title
Placebo + walking training (Dash)
Arm Type
Placebo Comparator
Arm Description
Placebo (whey powder isocaloric to BeneFlax) with exercise training (30-60 minutes walking training, 5 times a week) for 8 weeks; all participants encouraged to follow Dash Eating Plan.
Arm Title
BeneFlax® + flexibility training (Dash)
Arm Type
Experimental
Arm Description
BeneFlax (0.8 g, twice a day) with placebo exercise training (flexibility training, 5 times a week) for 8 weeks; all participants encouraged to follow Dash Eating Plan.
Arm Title
Placebo + flexibility training (Dash)
Arm Type
Sham Comparator
Arm Description
Placebo (whey powder isocaloric to BeneFlax) with placebo exercise training (flexibility training, 5 times a week) for 8 weeks; all participants encouraged to follow Dash Eating Plan.
Intervention Type
Dietary Supplement
Intervention Name(s)
BeneFlax®
Other Intervention Name(s)
Flaxseed lignan enriched complex
Intervention Description
Daily ingestion of 600 mg SDG/day in 1.6 g SDG-enhanced flax lignan (BeneFlax®) with walking training or flexibility training
Intervention Type
Behavioral
Intervention Name(s)
Walking training
Intervention Description
30-60 minutes walking training, 5 days/week.
Intervention Type
Behavioral
Intervention Name(s)
Flexibility training
Intervention Description
5 days/week; e.g. stretching training at home
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo (Whey Protein)
Intervention Description
0.6 g/day (an amount equal in volume to BeneFlax®) with walking training or flexibility training
Intervention Type
Behavioral
Intervention Name(s)
Dash Eating Plan
Intervention Description
Dietary Approaches to Stop Hypertension (DASH), a balanced eating plan - all participants in all treatment arms will be encouraged to adopt a DASH eating plan.
Primary Outcome Measure Information:
Title
Change in 24 h ambulatory systolic blood pressure
Description
Reduction in 24 h ambulatory systolic blood pressure at midpoint (week 4) and end (week 8) of the intervention relative to baseline value is the primary outcome of the intervention.
Time Frame
Baseline, week 4, and week 8
Secondary Outcome Measure Information:
Title
Change in body weight
Description
Change in body weight at midpoint (week 4) and end (week 8) of the intervention relative to baseline value.
Time Frame
Baseline, week 4, and week 8
Title
Heart rate
Time Frame
Baseline
Title
Glucometer fasting blood glucose
Description
Diabetes only; Blood glucose monitored to ensure intervention does not result in hypoglycemia.
Time Frame
Baseline
Title
Change in blood markers of safety and cardiovascular disease risk factors (clinical biochemical panel including fasting glucose, lipids, cholesterol, electrolytes, C-reactive protein)
Description
These parameters will be measured individual but reviewed as a composite to confirm safety and any change in cardiovascular disease risk.
Time Frame
Baseline, week 4, and week 8
Title
Blood levels of the flax lignan, secoisolariciresinol diglucoside (SDG), and its metabolites
Time Frame
Week 4
Title
Physical activity assessment tool (PASE)
Time Frame
Baseline
Title
Block Food Frequency Questionnaire
Time Frame
Baseline
Title
Change in Body composition by DXA (Dual-energy X-ray absorptiometry)
Description
Change in body composition at midpoint (week 4) and end (week 8) of the intervention relative to baseline value.
Time Frame
Baseline, week 4, and week 8
Title
Heart Rate
Time Frame
week 4
Title
Heart Rate
Time Frame
Week 8
Title
Change in lying and standing blood pressure
Description
Change in lying and standing blood pressure at midpoint (week 4) and end (week 8) of the intervention relative to baseline value.
Time Frame
Baseline, week 4, and week 8
Title
Respiratory rate
Time Frame
Baseline
Title
Respiratory rate
Time Frame
Week 4
Title
Respiratory rate
Time Frame
Week 8
Title
Block Food Frequency Questionnaire
Time Frame
Week 8
Title
Blood levels of the flax lignan, secoisolariciresinol diglucoside (SDG), and its metabolites
Time Frame
Week 8
Title
Glucometer fasting blood glucose
Description
Diabetes only; Blood glucose monitored to ensure intervention does not result in hypoglycemia.
Time Frame
Week 4
Title
Glucometer fasting blood glucose
Description
Diabetes only; Blood glucose monitored to ensure intervention does not result in hypoglycemia.
Time Frame
Week 8
Other Pre-specified Outcome Measures:
Title
Number of participants with adverse events as a safety measurement
Time Frame
Continuously throughout 9 weeks
Title
Number of participants with severe non-compliance with the protocol
Time Frame
Continuously throughout 9 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
60 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: High normal blood pressure (130/85 - 139/89) or stage I hypertension (140/90 - 150/90) Ability to follow simple instructions Exclusion Criteria: Age below 60 years. Individuals living in long term care homes. Individuals unable to walk for 30 minutes. Unstable diabetes, or diabetics taking insulin (note: eligible diabetic participants will undergo additional testing during the study ). Current cancer or diagnosed with cancer in the past 2 years. Significant liver or other gastrointestinal disorder including inflammatory bowel disease. (While constipation is the most common gastrointestinal problem in the elderly, it would not be a contraindication) Significant kidney disorder. Have taken oral antibiotics in the past three months Unstable or severe cardiac disease, recent myocardial infarction, or stroke (either in past 6 months or significantly affecting physical mobility). Unstable other medical disease including, but not limited to, pulmonary disorder, epilepsy and genitourinary disorder. Migraine with aura within the last year (as this is a risk factor for stroke). Current diagnosis of a bleeding condition, or at risk of bleeding. Significant immune-compromise. Current use of hormone replacement therapy (except thyroid). Current use of blood pressure medications and/or diuretics Current use of flax seed supplement Participation in any other clinical trial with an investigational agent within one month prior to randomization.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jane Alcorn, PhD
Organizational Affiliation
University of Saskatchewan
Official's Role
Principal Investigator
Facility Information:
Facility Name
College of Pharmacy, University of Saskatchewan
City
Saskatoon
State/Province
Saskatchewan
ZIP/Postal Code
S7N 5E5
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
20883417
Citation
Peterson J, Dwyer J, Adlercreutz H, Scalbert A, Jacques P, McCullough ML. Dietary lignans: physiology and potential for cardiovascular disease risk reduction. Nutr Rev. 2010 Oct;68(10):571-603. doi: 10.1111/j.1753-4887.2010.00319.x.
Results Reference
background
PubMed Identifier
17987126
Citation
Pan A, Sun J, Chen Y, Ye X, Li H, Yu Z, Wang Y, Gu W, Zhang X, Chen X, Demark-Wahnefried W, Liu Y, Lin X. Effects of a flaxseed-derived lignan supplement in type 2 diabetic patients: a randomized, double-blind, cross-over trial. PLoS One. 2007 Nov 7;2(11):e1148. doi: 10.1371/journal.pone.0001148.
Results Reference
background
PubMed Identifier
18053310
Citation
Zhang W, Wang X, Liu Y, Tian H, Flickinger B, Empie MW, Sun SZ. Dietary flaxseed lignan extract lowers plasma cholesterol and glucose concentrations in hypercholesterolaemic subjects. Br J Nutr. 2008 Jun;99(6):1301-9. doi: 10.1017/S0007114507871649. Epub 2007 Dec 6.
Results Reference
background
PubMed Identifier
19370038
Citation
Cornish SM, Chilibeck PD, Paus-Jennsen L, Biem HJ, Khozani T, Senanayake V, Vatanparast H, Little JP, Whiting SJ, Pahwa P. A randomized controlled trial of the effects of flaxseed lignan complex on metabolic syndrome composite score and bone mineral in older adults. Appl Physiol Nutr Metab. 2009 Apr;34(2):89-98. doi: 10.1139/H08-142.
Results Reference
background
PubMed Identifier
24126178
Citation
Rodriguez-Leyva D, Weighell W, Edel AL, LaVallee R, Dibrov E, Pinneker R, Maddaford TG, Ramjiawan B, Aliani M, Guzman R, Pierce GN. Potent antihypertensive action of dietary flaxseed in hypertensive patients. Hypertension. 2013 Dec;62(6):1081-9. doi: 10.1161/HYPERTENSIONAHA.113.02094. Epub 2013 Oct 14.
Results Reference
background
PubMed Identifier
20003621
Citation
Adolphe JL, Whiting SJ, Juurlink BH, Thorpe LU, Alcorn J. Health effects with consumption of the flax lignan secoisolariciresinol diglucoside. Br J Nutr. 2010 Apr;103(7):929-38. doi: 10.1017/S0007114509992753. Epub 2009 Dec 15.
Results Reference
background

Learn more about this trial

Flaxseed Lignan Supplementation in Elderly Participants With Stage I Hypertension

We'll reach out to this number within 24 hrs